Immune dysfunction in Rett syndrome patients revealed by high levels of serum anti-N(Glc) IgM antibody fraction by Papini, Anna Maria et al.
Research Article
Immune Dysfunction in Rett Syndrome Patients Revealed by
High Levels of Serum Anti-N(Glc) IgM Antibody Fraction
Anna Maria Papini,1,2,3 Francesca Nuti,1,2 Feliciana Real-Fernandez,4 Giada Rossi,1,5
Caterina Tiberi,1,5 Giuseppina Sabatino,1,2 Shashank Pandey,1,2 Silvia Leoncini,6,7
Cinzia Signorini,7 Alessandra Pecorelli,6,7 Roberto Guerranti,8,9 Solange Lavielle,10
Lucia Ciccoli,7 Paolo Rovero,1,5 Claudio De Felice,11 and Joussef Hayek6
1 Laboratory of Peptide and Protein Chemistry and Biology, University of Florence, Via della Lastruccia 13, 50019 Sesto Fiorentino, Italy
2 Department of Chemistry “Ugo Schiff”, University of Florence, 50019 Sesto Fiorentino, Italy
3 Laboratory of PeptLab-SOSCO-EA4505, University of Cergy-Pontoise, 5 mail Gay Lussac, 95031 Cergy-Pontoise CEDEX, France
4 Toscana Biomarkers Srl, 53100 Siena, Italy
5 Section of Pharmaceutical and Nutraceutical Sciences, Department NeuroFarBa, University of Florence, 50019 Sesto Fiorentino, Italy
6Child Neuropsychiatry Unit, University Hospital, Azienda Ospedaliera Universitaria Senese (AOUS), 53100 Siena, Italy
7 Department of Molecular and Developmental Medicine, University of Siena, 53100 Siena, Italy
8Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy
9 Clinical Pathology Laboratory Unit, University Hospital, AOUS, 53100 Siena, Italy
10Laboratory of BioMolecules, Sorbonne Universite´ UPMC Paris 06, CNRS-ENS, 75005 Paris, France
11Neonatal Intensive Care Unit, University Hospital, AOUS, 53100 Siena, Italy
Correspondence should be addressed to Anna Maria Papini; annamaria.papini@unifi.it
Received 24 July 2014; Accepted 15 September 2014; Published 15 October 2014
Academic Editor: Douglas C. Hooper
Copyright © 2014 Anna Maria Papini et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Rett syndrome (RTT), a neurodevelopmental disorder affecting exclusively (99%) female infants, is associated with loss-of-function
mutations in the gene encodingmethyl-CpG binding protein 2 (MECP2) and, more rarely, cyclin-dependent kinase-like 5 (CDKL5)
and forkhead box protein G1 (FOXG1). In this study, we aimed to evaluate the function of the immune system by measuring
serum immunoglobulins (IgG and IgM) in RTT patients (𝑛 = 53) and, by comparison, in age-matched children affected by non-
RTT pervasive developmental disorders (non-RTT PDD) (𝑛 = 82) and healthy age-matched controls (𝑛 = 29). To determine
immunoglobulins we used both a conventional agglutination assay and a novel ELISA based on antibody recognition by a surrogate
antigen probe, CSF114(Glc), a syntheticN-glucosylated peptide. Both assays provided evidence for an increase in IgM titer, but not
in IgG, in RTTpatients relative to both healthy controls and non-RTTPDDpatients.The significant difference in IgM titers between
RTT patients and healthy subjects in the CSF114(Glc) assay (𝑃 = 0.001) suggests that this procedure specifically detects a fraction
of IgM antibodies likely to be relevant for the RTT disease. These findings offer a new insight into the mechanism underlying the
Rett disease as they unveil the possible involvement of the immune system in this pathology.
1. Introduction
Rett syndrome (RTT), an X-linked neurodevelopment disor-
der affecting almost exclusively females, is associated with a
single monogenic mutation (methyl-CpG binding protein 2,
MeCP2) in up to 95% of cases [1], more rarely by mutations
in cyclin-dependent kinase-like 5 (CDKL5) [2], and forkhead
box protein G1 (FOXG1) gene [3]. RTT syndrome, formerly
placed in the heterogeneous group of autism spectrum
disorders (ASD), is now regarded as a distinct pathological
entity. The recently issued clinical criteria for RTT diag-
nosis have clearly defined the core features of the disease.
Approximately 80% of RTT patients show the typical clinical
features: early neurological regression, followed by loss of
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acquired cognitive, social, and motor skills in a typical four-
stage neurological regression, together with development of
autistic behavior [4].
RTT patients with atypical clinical presentation usually
harbor CDKL5 (early seizure variant, ESV) or FOXG1 (con-
genital variant, CV) mutations, while the preserved speech
variant (PSV) is usually linked to MeCP2 mutations [5].
Despite almost two decades of research into the functions and
role of MeCP2, surprisingly little is known about the mecha-
nisms leading fromMeCP2 deficiency to disease expression.
Research, focused largely on in vivo functions of MeCP2
in transgenic mice lacking the Mecp2 gene, has provided
evidence for a repressive action of the transcription factor on
neuronal genes associated with dendrite arborization as well
as other neuronal functions [6].
In contrast, evidences indicate that, in central nervous
systems (CNS) cells other than neurons, as astrocytes and
microglia, MeCP2 ablation impairs upregulation of genes,
which support dendritic arborization, and the inherent
phagocytic activity of microglia [7, 8]. In light of demon-
strated involvement of microglia in disease progression in
Mecp2-null mice, we hypothesize the coexistence of a pertur-
bation of the immune system in RTT patients. In particular, a
derangement of microglia immune responsiveness might be
likely to occur in these patients, as neuroinflammation is a
powerful modulator of the CNS immune system.
In pathological CNS conditions, such as RTT and others
(e.g., multiple sclerosis, MS) in which neither the antibodies
nor the antigens involved in the disease are known, the
detection of putative antibodies in biological fluids may
be achieved by employing a library of unnatural peptides,
which, by virtue of their conformation and posttranslational
modifications (e.g., N-glucosylation), recognize and bind to
the relevant antibodies [9, 10]. We have previously used
this approach to characterize antibodies present in multiple
sclerosis patients’ serum by applying a further refinement,
that is, the N-glucosylation, to the molecule of the surrogate
peptide antigen [11, 12]. The rationale for this chemical mod-
ification stems from the recognition that N-glucosylation
is a pervasive feature of biomolecules occurring in CNS
pathologies characterized by neuronal disruption. In this
work, we took advantage of prior experience gained on MS
antibodies using the CSF114(Glc) peptide antigenic probe,
with the aim of investigating the presence of antibodies in
serumofRTTpatients, and by comparison to healthy controls
and non-RTT pervasive developmental disorders patients.
2. Material and Methods
2.1. Patients. In this study, a total of 164 patients were
enrolled. This population consisted of three clearly distin-
guishable groups: the RTT syndrome group versus non-
RTT pervasive developmental disorders (non-RTT PDD)
group on the basis of the clinical features and the presence
of mutated RTT-related genes and healthy, age-matched
controls. The RTT group consisted of 53 patients (mean age
12.8 ± 10.7 years) who were referred to our clinical unit (a
referral center for a vast region in central Italy) subdivided
into 𝑛 = 41 (77.4%) with classical clinical presentation with
proven MeCP2 gene mutation and 𝑛 = 12 (12.6%) atypical
presentation (of whom 𝑛 = 9, 𝑛 = 2, and 𝑛 = 1 linked
to CDKL5, FOXG1, and MeCP2 mutations, resp.). These
patients were hospitalized for 1 week every 6 months, in the
Child Neuropsychiatric Unit, University Hospital Azienda
Ospedaliera Universitaria Senese of Siena (Italy), during the
course of the study. Criteria for inclusion in the study were
clinical diagnosis of RTT syndrome coupled with positive
identification for the presence/absence of mutated MeCP2,
CDKL5, or FOXG1 genes. The age-matched non-RTT PDD
group consisted of 82 patients (mean age 13.0 ± 9.5 years), as
diagnosed on the basis of well-established criteria.They were
recruited from those attending our unit for routine clinical
follow-up. Blood samplings in the patients’ group were
performed during the routine follow-up study at hospital
admission, while the samples from the control group were
carried out during routine health checks, sports, or blood
donations, obtained during the periodic clinical checks. The
healthy control subjects were age-matched.
Recruitment of patients was performed in a diagnostic
workup context. Patients were selected randomly and not
previously tested for immune reactivity by ELISA. This
study was approved by the Institutional Review Board of
Azienda Ospedaliera Universitaria Senese. Parents, tutors,
or guardians of all the participants provided their written
informed consent for the minors to participate in this study.
The study design, methods, and consent procedure were
approved by the Institutional Review Board of Azienda
Ospedaliera Universitaria Senese. All the data used in this
study was anonymized.
2.2. Total Plasma Immunoglobulins. Determination of total
plasma IgG and IgM was performed using the Cobas 6000
system (Roche Diagnostics). Briefly, the Roche test is based
on the principle of agglutination immunoassay where anti-
Ig antibodies react with the antigen in the sample, forming
an antigen-antibody complex, which, after agglutination, is
measured turbidimetrically. It is important to note that this
method is standard in the clinical chemistry laboratories
and is independent from the recognition of the synthetic N-
glucosylated peptide epitope.
2.3. Determination of Serum Antibodies by SP-ELISA. Anti-
body responses were determined in SP-ELISA. Ninety-six
well activated polystyrene ELISA plates (NUNC Maxisorp
Sigma) were coated with 1 𝜇g per 100 𝜇L of glycopeptide
in carbonate buffer 0.05M (pH 9.6) and incubated at +4∘C
overnight. After five washes with saline containing 0.05%
Tween 20, nonspecific binding sites were blocked by fetal
bovine serum (FBS), 10% in saline Tween 20 (100 𝜇L per well)
at room temperature for 60min. Sera diluted from 1 : 100
to 1 : 10,000 were applied at +4∘C overnight in saline/Tween
20/10% FBS. After five washes, we added to each well 100𝜇L
of alkaline phosphatase conjugated antihuman IgM (diluted
1 : 200 in saline/Tween 20/FBS; Sigma) or IgG (diluted 1 : 8000
in saline/Tween 20/FBS; Sigma). After 3 h at room tem-
perature incubation and five washes, 100𝜇L of substrate
solution consisting of 1mgmL−1 p-nitrophenyl phosphate
(Sigma) in 10% diethanolamine buffer was applied. After
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Figure 1: Elevated autoantibodies anti-CSF114(Glc) and total IgM titers in Rett syndrome. (a) Anti-CSF114(Glc) serum IgM antibody titers
by the N-glucopeptide-based immunoenzymatic assay: comparison between RTT and non-RTT PDD patients. (b) Total plasma IgM levels
detected by the conventional agglutination assay (RocheCobas 6000).Data are plotted as notched box dot plotswithmedians and interquartile
range values. 𝑃 values refer to nonparametric Kruskal-Wallis analysis of variance. Solid rectangles indicate outlier values, ∗𝑃 < 0.05.
30min, the reaction was stopped with 1M NaOH (50 𝜇L),
and the absorbance was read in a multichannel ELISA reader
(Tecan Sunrise) at 405 nm. ELISA plates, coating conditions,
reagent dilutions, buffers, and incubation times were tested
in preliminary experiments. Antibody levels are expressed
as absorbance in arbitrary units at 405 nm (sample dilution
1 : 100).
2.4. Data Analysis. All variables were tested for normal dis-
tribution (D’Agostino-Pearson test) and data were presented
as either means ± standard deviation (SD) for normally
distributed variables or medians and interquartile range val-
ues for non-normally distributed data. Differences between
groups were evaluated. The efficiency of anti-CSF114(Glc)
IgM in discriminating RTT from either non-RTT PDD
patients or healthy control subjects was evaluated using a
receiver operating characteristic (ROC) curve analysis. Two-
tailed P values of less than 0.05 were considered significant.
Correction for multiple comparisons was made (Bonferroni’s
correction). The MedCalc version 12.1.4 statistical software
package (MedCalc Software, Mariakerke, Belgium) was used.
3. Results
The presence of putative serum antibodies (Abs) in the
selected patients’ population and healthy subjects was eval-
uated by both a conventional agglutination procedure and
solid-phase ELISA, using an N-glucosylated 𝛽-turn peptide
probe, termed CSF114(Glc). The IgM antibody titers clearly
segregate the two patient groups (Figure 1).
In fact, the individual IgM antibody titers found in RTT
patients were significantly higher than those in the control
groups, that is, both healthy subjects and non-RTT PDD
patients. These changes of IgM antibodies were detected
either by assaying antibodies through an agglutination assay
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Figure 2: Correlation between anti-CSF114(Glc) serum IgM anti-
body titers and total plasma IgM levels in RTT patients’ sera.
routinely used in the hospital laboratory (Roche Cobas 6000)
or by the N-glucopeptide-based immunoenzymatic assay
based on the novel CSF114(Glc) antigen probe (Figures 1(a)
and 1(b), 𝑃 < 0.05). Although the two assays are not directly
comparable, since they provide different absolute values of
antibody titers, nonetheless they both indicate a consistent
relative increase of serum IgM in the RTT group. Moreover,
we observed a linear correlation between anti-CSF114(Glc)
serum IgMantibody titers and total plasma IgM levels in RTT
patients (Figure 2).
Whereas the agglutination assay detects the total serum
antibody population, the CSF114(Glc) identifies a small frac-
tion of this population.These observed differences are, in our
view, evidence that CSF114(Glc) captures specific antibodies
associated with the disease.
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Figure 3: Receiver operating characteristic (ROC) analysis for anti-CSF114(Glc) serum IgM antibody titer. ROC curve discriminates RTT
patients versus healthy subjects (a) and RTT patients from non-RTT PDD patients (b). Abbreviations list: AUC: area under the curve; SE:
standard error; C.I: confidence intervals; L.R.: likelihood ratio. a95% confidence interval; blikelihood ratio.
Receiver operating characteristic (ROC) curves indicated
that anti-CSF114(Glc) titers are able to discriminate RTT
syndrome from either non-RTT PDD patients or control
subjects (Figure 3).
At variance, while the CSF114(Glc) antigen failed to
detect significant differences in auto IgG auto-antibody titers
among the three groups (RTT vs. non-RTT PDD vs. healthy
controls), the total plasma IgG titer in the RTT population
was significantly decreased. (Supplementary Figure 1 in
Supplementary Material available online at http://dx.doi.org/
10.1155/2014/260973).
4. Discussion
This report describes the changes observed in serum immu-
noglobulins IgM and IgG, in RTT patients in comparison
to healthy subjects and patients afflicted by diffused autis-
tic traits (i.e., non-RTT PDD). The two patients groups
were defined on the basis of the presence of known gene
mutations (mainly MeCP2) for the RTT group and of well-
established diagnostic criteria for the non-RTT PDD group.
Although a number of studies have addressed the relationship
between RTT and immune system dysfunction, these have
mainly focused on their influence on peripheral immune
cells [8], although two early reports investigated humoral
immunity in RTT patients, observing evidences of immune
system activation [13, 14]. Here, we demonstrate that RTT
patients show a consistent and highly significant increase
of the serum IgM fraction relative to both healthy controls
and non-RTT PDD patients group. This was shown by
determining the serum IgM titer by two independent assay
procedures. We assayed immunoglobulin by a conventional,
widely used, hospital procedure based on agglutination and
as a complementary assay, an antibody recognition procedure
based on a surrogate antigen, termed CSF114(Glc), a peptide
bearing N-glucosylation on its moiety. In our view, the IgM
fraction recognized byCSF114(Glc), tiny in comparison to the
large one detected by the agglutination procedure, represents
an antibody pool of pathophysiological relevance for this
disease. Supporting this view is the remarkable specificity of
interaction betweenCSF114(Glc) and IgMantibodies demon-
strated by the receiver operating curve, widely considered a
test of accuracy for discriminating between diseased patients
and normal subjects. Thus, it appears that the RTT patients
Journal of Immunology Research 5
group can be distinguished with confidence on the basis of
serum IgM titer detected by the CSF114(Glc)-based assay. It
is of interest that the large serum IgM increases, noted here,
were also observed by us and others, in a subset of multiple
sclerosis patients as well as in meningitis and encephalitis
patients ([14] and references therein). It is plausible that
the IgM changes, noted in these CNS pathologies, reflect a
common underlying mechanism, most probably a pervasive
neuroinflammation. We suggest that the association between
neuroinflammation and the observed serum IgM rise might
be causal to the RTT disease initiation and/or progression.
The question arises whether the neuronal derangement elicits
the immune response, or conversely, the immunedysfunction
might trigger the neuroinflammation. Although the present
observations do not answer this “chicken or egg question,”
there are indications that IgM overexpression represents
primarily a line of defense against noxious stimuli.
In contrast to IgM fraction, we found small changes
in the serum IgG of RTT patients when assayed with the
agglutination assay, while the CSF114(Glc) assay performed
poorly in detecting IgG antibodies.
Further considerations concern the growing research area
of epigenetics, which reportedly appears to be involved in
autoimmune diseases. These are generally considered to be
caused by a combination of epigenetic modification, dereg-
ulated immunomodulation, and environmental factors. Sev-
eral single-nucleotide polymorphisms (SNPs) at an X chro-
mosome locus harboring the MeCP2 gene have previously
been shown to be associated with susceptibility to systemic
lupus erythematosus, as well as with a variety of systemic
autoimmune diseases [15]. Recent reports on experimental
models in mice have placed microglia at the center stage of
the RTT progression, as the Mecp2-deficient mice reproduce
most of the human RTT phenotype features [7, 16]. Because
microglia exert a prominent immune surveillance role in the
CNS, it is likely that the large serum IgM increase reflects and
signals a severe disturbance of immune regulation in brain
[17].
In conclusion, the results of this work contribute to elu-
cidate that the two disease conditions such as Rett syndrome
and the diffuse autism, seemingly contiguous as they share
some behavioral traits, are in fact dramatically different for
their severity, life-span expectancy, and, as we now learn,
immune system derangement.
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